Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy Volunteer

Interventions: Drug: placebo
Drug: tocilizumab [RoActemra/Actemra]

First Posted Date: 2013-11-25

Last Posted Date: 2015-11-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 18

Registration Number: NCT01991990

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Completed

Conditions: Malignant Melanoma

First Posted Date: 2013-11-21

Last Posted Date: 2018-06-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 339

Registration Number: NCT01990248

Locations: 🇦🇹
LKH Feldkirch; Onkologie, Feldkirch, Austria
🇦🇹
Ordensklinikum Linz Elisabethinen ; Dermatologie, Linz, Austria
🇦🇹
Krankenhaus Hietzing Wien, Wien, Austria

and more 77 locations

A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment

Terminated

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib

First Posted Date: 2013-11-21

Last Posted Date: 2016-09-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 33

Registration Number: NCT01990261

Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Atezolizumab
Drug: Cobimetinib

First Posted Date: 2013-11-20

Last Posted Date: 2019-12-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 153

Registration Number: NCT01988896

Locations: 🇺🇸
Massachusets General Hospital Clinical Trial Network and Institute, Boston, Massachusetts, United States
🇺🇸
Compass Oncology, Portland, Oregon, United States
🇺🇸
Texas Oncology, P.A., Arlington, Texas, United States

and more 18 locations

A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: tocilizumab

First Posted Date: 2013-11-20

Last Posted Date: 2017-03-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 100

Registration Number: NCT01988012

A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies

Phase 1

Completed

Conditions: Solid Tumors, Advanced Solid Tumors

Interventions: Drug: RO6870810

First Posted Date: 2013-11-19

Last Posted Date: 2018-01-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 52

Registration Number: NCT01987362

Locations: 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma

Phase 3

Completed

Conditions: Lymphoma, Non Hodgkin

Interventions: Drug: Rituximab

First Posted Date: 2013-11-19

Last Posted Date: 2018-12-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 140

Registration Number: NCT01987505

Locations: 🇪🇸
Hospital General de Castellon; Servicio de Hematologia, Castellon, Spain
🇪🇸
Hospital Universitario Virgen de las Nieves; Servicio de Hematologia, Granada, Spain
🇪🇸
Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain

and more 36 locations

A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Non-Biologic DMARDs
Drug: Tocilizumab
Drug: Methotrexate

First Posted Date: 2013-11-19

Last Posted Date: 2017-06-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 150

Registration Number: NCT01987479

Locations: 🇳🇱
Gelre Ziekenhuizen; Reumatologie, Apeldoorn, Netherlands
🇳🇱
Antonius Ziekenhuis Sneek; Department of Rheumatology, Sneek, Netherlands
🇳🇱
Amphia ziekenhuis, locatie langendijk, Breda, Netherlands

and more 17 locations

A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Lebrikizumab
Drug: Placebo

First Posted Date: 2013-11-19

Last Posted Date: 2017-05-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 230

Registration Number: NCT01987492

Locations: 🇧🇪
Clin Univ de Bxl Hôpital Erasme, Bruxelles, Belgium
🇦🇺
Monash Medical Centre; Respiratory and Sleep Medicine, Clayton, Victoria, Australia
🇧🇪
Longartsenpraktijk, Genk, Belgium

and more 68 locations

A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Alectinib
Drug: Posaconazole

First Posted Date: 2013-11-14

Last Posted Date: 2016-10-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 23

Registration Number: NCT01984229

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy